Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) kept active in profitability ratio analysis, on current situation shares price rose 16.33% to $1.14. The total volume of 2.19 Million shares held in the session, while on average its shares change hands 422.24 shares.
Acura Pharmaceuticals, Inc. (ACUR) reported that it is exploring a full range of financing and strategic alternatives, including a possible sale of the company. The Company has retained Roth Capital Partners to assist in this process. Alternatives to a sale of the company include a capital raising transaction, a licensing transaction and a sale of certain assets.
There can be no assurance a transaction will result from this process and the company does not intend to disclose additional details unless and until it has entered into a specific transaction.
Efficiency Evaluation in Focus
Entering into profitability analysis, the co has noticeable returns on equity ratio of -285.10%, which discloses how corporation’s management efficiently generates profit from shareholders invested money. The returns on investment very popular metric among passive investors, it stands at -25.60%, when it lies in positive figure than security is feasible for investment or goes for higher ROI stocks. The -79.80% returns on assets presents notable condition of firm. Mostly ROA known as a comparative measure, it is best to compare it against a firm’s previous ROA numbers or the ROA of a same firm. ACUR is presenting price to cash flow of 3.15
To stick with focus on profitability valuation, Inovio Pharmaceuticals, Inc. (NASDAQ:INO) also listed in significant eye catching mover, INO attains returns on investment ratio of -18.30%, which suggests it’s viable on security that has lesser ROI. Turns back to returns ratios, the co’s returns on assets calculated as -18.30%; that gives an idea as to how efficient management is at using its assets to generate earnings. Finally yet importantly, returns on equity stands at -39.90%.
EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at 29.90%, and looking further price to next year’s EPS is -18.80%. While take a short look on price to sales ratio, that was 14.68.